P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
P Bartolucci,
K Ataga,
M Callaghan,
L De Franceschi,
C Minniti,
A Alexandrou,
D Imbs,
R Fox,
H Patel,
A Sostelly,
J Schimmel
Affiliations
P Bartolucci
1 University Paris-East Créteil, Sickle Cell Referral Center - UMGGR & IMRB, Laboratory of Excellence LABEX GRex, Créteil, FRANCE
K Ataga
2 UTHSC Center for Sickle Cell Disease, Memphis, TN, UNITED STATES
M Callaghan
3 Division of Pediatric Hematology/Oncology, Central Michigan University SOM, Children’s Hospital of Michigan, Detroit, MI, UNITED STATES
L De Franceschi
4 Department of Medicine, University of Verona and AOUI Verona, Verona, ITALY
C Minniti
5 Albert Einstein College of Medicine, Bronx, New York, NY, UNITED STATES
A Alexandrou
6 Roche Products Limited, Welwyn Garden City, UNITED KINGDOM
D Imbs
7 Certara, Inc., Paris, FRANCE
R Fox
8 Parexel International, Uxbridge, UNITED KINGDOM
H Patel
9 Genentech, Inc., South San Francisco, CA, UNITED STATES
A Sostelly
10 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND
J Schimmel
11 Icahn School of Medicine at Mount Sinai, Department of Emergency Medicine, New York. NY, UNITED STATES
